| Literature DB >> 36164338 |
Lavinia Schüler Faccini1, Luciana Friedrich1, Sara Kvitko de Moura1, Fernanda Diffini Santa Maria1, Steice da Silva Inácio de Bone1.
Abstract
Introduction: The association between the virus prenatal infection by Zika virus (ZIKV) and central nervous system disorders has been well established and it has been described as the Congenital Syndrome Associated to the Zika Virus (CSZ). However, the neurological development in those patients is still an object of study. The main differential diagnosis is the Cytomegalovirus (CMV). Objective: Describe the involvement of microcephalic patients affected by the congenital infection by the Zika Virus or CMV. Methodology: Data has been collected from microcephalic patients whose birth took place after 2016 and which also had the congenital infection confirmed or presumed. The researched data consists in: congenital infection, head circumference from birth, presence of epilepsy, treatment by mono or polytherapy, electroencephalographic patterns, neurological physical examination and evaluation of gross motor development.Entities:
Keywords: Congenital infection; Cytomegalovirus; Epilepsy; Microcephaly; Zika virus
Year: 2022 PMID: 36164338 PMCID: PMC9507981 DOI: 10.1016/j.ensci.2022.100417
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Most common changes identified during birth and within the 1st month of life.
| Neuroimaging Findings | Clinical Findings |
|---|---|
| Brain calcifications | Changes in muscle tone |
| Cerebral cortical developmental disorder | Posture change |
| Frontal parietal predominance of cortical thickening | Primitive reflexes exaggeration |
| Polymicrogyria | Hyperexcitability |
| Simplification of the brain gyri patterns / sulci patterns | Irritability |
| Ventriculomegaly/ Ventricular dilation | Epileptic seizures |
| Changing of the posterior fossa pattern | Sucking and swallowing difficulties |
| Brainstem Hypoplasia, cerebellum, callosal commissure | Dysphagia |
| Fundoscopy changes (retina and optic nerve) | |
| Abnormal eye movements |
Source: Adapted from Brazil (2017).
Clinical, epileptic, and EEG characteristics of the sample.
| Name | Sex | Cephalic Perimeter Measure (cm) | Cephalic Perimeter at birth | Resulted of collected ZIKV test | Congenital Infection | Epilepsy | Types of epilepsy | Spasms | Antiepileptic usage | Medications | Background Activity -Asymmetrical | Background Activity - Disorganized | Epileptiform activity | GMFSC -Classification | Cerebral Palsy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EGCM | Male | 31 | <2SD | Negative | CMV | No | – | – | – | – | – | – | 2 | No | |
| TDPD | Male | 28,5 | <3SD | Negative | CMV | Yes | Generalized | Yes | Monotherapy | Valproate | Yes | Yes | Generalized | 5 | Yes |
| ILP | Male | 29 | <3SD | Not tested | CMV | Yes | Generalized | Yes | Polytherapy | Phenobarbital and Valproate | Yes | Yes | Multifocal | 5 | Yes |
| JMM | Male | 30,8 | <2SD | Not tested | Presumed Infection by ZIKV | Yes | Generalized | No | Polytherapy | Clonazepam and Valrpoate | Yes | Yes | Generalized | 4 | Yes |
| YVMW | Female | 26,5 | <3SD | Positive | ZIKV | Yes | Generalized | No | Polytherapy | Clonazepam and Phenobarbital | Yes | Yes | Multifocal | 5 | Yes |
| JVA | Male | 29.5 | <2SD | Not tested | Presumed Infection by ZIKV | No | – | – | – | – | – | – | 5 | Yes | |
| VIC | Female | 27 | <3SD | Not tested | ZIKV | Yes | Generalized | No | Monotherapy | Phenobarbital | Yes | Yes | Generalized | 4 | Yes |
| ILOC | Female | 30,5 | <2SD | Negative | CMV | No | – | – | – | – | – | – | 1 | No | |
| LCB | Female | 32 | <2SD | Positive | ZIKV | No | – | – | – | – | – | – | 1 | No | |
| KAJPM | Male | 30 | <2SD | Not tested | ZIKV | Yes | Generalized | No | Monotherapy | Valproate and Phenobarbital | Yes | Yes | Generalized | 3 | Yes |
| EGMS | Male | 30 | <2SD | Not tested | ZIKV | Yes | Generalized | No | Monotherapy | Valproate | Yes | Yes | Multifocal | 5 | Yes |
| HKSR | Female | 30 | <3SD | Negative | CMV | Yes | Generalized | No | Polytherapy | Valproate and Phenobarbital | Yes | Yes | Multifocal | 5 | Yes |
| LNP | Female | 28 | <3SD | Negative | Presumed Infection by ZIKV | No | – | – | – | – | – | – | 3 | Yes | |
| MLSL | Female | 30 | <2SD | Negative | CMV | Yes | Generalized | Yes | Polytherapy | Valproate and Vigabatrin | Yes | Yes | Hipsarritmia | 5 | Yes |
| HAB | Female | 28 | <3SD | Not tested | ZIKV | No | – | – | – | – | – | – | 5 | Yes | |
| LHLM | Female | 30 | <3SD | Negative | Presumed Infection by ZIKV | Yes | Generalized | Yes | Polytherapy | Valproate, Clobazam and Vigabatrin | Yes | Yes | Hipsarritmia | 5 | Yes |
| ALP | Female | 30 | <2SD | Not tested | CMV | No | – | – | – | – | – | – | 1 | No | |
| LRFSP | Male | 29 | <3SD | Not tested | Presumed Infection by ZIKV | Yes | Generalized | Yes | Polytherapy | Valproate, Phenobarbital and Levetiracetam | Yes | Yes | Multifocal | 5 | Yes |
| AA | Male | 29 | <3SD | Negative | CMV | No | – | – | – | – | – | – | 3 | Yes | |
| BGR | Male | 30 | <3SD | Negative | Presumed Infection by ZIKV | Yes | Generalized | Yes | Polytherapy | Valproate and Clobazam | Yes | Yes | Focal | 5 | Yes |
| AFR | Male | 29 | <2SD | Not tested | CMV | Yes | Generalized | Yes | Polytherapy | Valproate, Phenobarbital and Levetiracetam | Yes | Yes | Hipsarritmia | 5 | Yes |
Samples' description.
| Sex | Female | 10 (47,6%) |
| Male | 11 (52,4%) | |
| Completed Prenatal | Yes | 20 (95,2%) |
| No | 1 (4,8%) | |
| ZIKV's collect during pregnancy | Yes | 11 (52,4%) |
| No | 10 (47,6%) | |
| Resulted of collected ZIKV test | Positive | 2 (9,5%) |
| Negative | 9 (42,9%) | |
| Not tested | 10 (47,6%) | |
| Cephalic Perimeter Measure | Females | 29,2 ± 1,73 cm |
| Males | 29,61 ± 0,80 cm | |
| Cephalic Perimeter at birth | Z < −2 | 10 (47,6%) |
| Z < −3 | 11 (52,4%) | |
| Congenital Infection | CMV | 9 (42,9%) |
| ZIKV | 6 (28,6%) | |
| Presumed Infection by ZIKV | 6 (28,6%) |
Cerebral Involvement in patients with CMV, CSZ confirmed or presumed.
| CMV Number/Total (%) | CSZ confirmed or presumed Number/ Total (%) | Fisher Exact Test | |
|---|---|---|---|
| 0,673 | |||
| Yes | 5 (55,6%) | 8 (66,7%) | |
| No | 4 (44,4%) | 4 (44,4%) | |
| 4/5 (80%) | 3/8 (37,5%) | 0,266 | |
| Monotherapy | 1/5 (20%) | 3/8 (37,5%) | |
| Polytherapy | 4/5 (80%) | 5/8 (62,5%) | |
| Asymmetrical | 5/5 (100%) | 8/8 (100%) | |
| Disorganized | 5/5 (100%) | 8/8 (100%) | |
| Focal | 0/5 (0%) | 1/8(12,5%) | |
| Multifocal | 2/5 (40%) | 3/8 (37,5%) | |
| Generalized | 1/5 (20%) | 3/8 (37,5%) | |
| Hipsarritmia | 2/5 (40%) | 1/8 (12,5%) | |
| 6/9 (66,7%) | 11/12 (91,7%) | 0,355 | |
| 5/9 (55,6%) | 7/12 (58,3%) | 0,077 |
Comparison between the GMFCS score and the Z score of the Cephalic Perimeter.
| GMFCS Classification | I Number/ Total (%) | II Number/ Total l (%) | III Number/ Total (%) | IV Number/ Total (%) | V Number/ Total (%) | Total | |
|---|---|---|---|---|---|---|---|
| CP < −2 | 3/10(100%) | 1/10(100%) | 1/10(33,3%) | 1/10 (50%) | 4/10(33,3%) | 10 | 0,273 |
| CP < −3 | 0/11 (0%) | 0/11 (0%) | 2/11(66,7%) | 1/11 (50%) | 8/11(66,7%) | 11 |
Comparison between the GMFSC and the epilepsy prevalence and its cause.
| GMFCS Classification | I Number/ n = 3(%) | II Number/ n = (%) | III Number/ Total (%) | IV Number/ Total (%) | V Number/ Total(%) | P value |
|---|---|---|---|---|---|---|
| With Epilepsy | 0/3 (0%) | 0/1 (0%) | 1/3(33,3%) | 2/2(100%) | 10/12(83,3%) | 0,007 |
| CMV | 2/3 (66,7%) | 1/1 (100%) | 1/3(33,3%) | – | 5/12 (41,7%) | 0,622 |
| ZIKV + probable ZIKV | 1/3 (33,3%) | – | 2/3 (66,7%) | 2/2(100%) | 7/12 (58,3%) |